Ecthymatous skin eruption during therapy with cetuximabNAVARINI, Alexander A; KAMACHAROVA, Ilina; KERL, Katrin et al.EJD. European journal of dermatology. 2011, Vol 21, Num 2, pp 282-283, issn 1167-1122, 2 p.Article

Psoriasis induced by cetuximab: A paradoxical adverse effectMAS-VIDAL, Albert; COTO-SEGURA, Pablo; GALACHE-OSUNA, Cristina et al.Australasian journal of dermatology. 2011, Vol 52, Num 1, pp 56-58, issn 0004-8380, 3 p.Article

Cetuximab : Significant clinical value after platinum failureJournal of cancer research and clinical oncology. 2006, Vol 132, pp 11-13, issn 0171-5216, 3 p., SUP3Conference Paper

Éruptions acnéiformes induites par le cétuximab = Acneiform eruptions induced by cetuximabWALON, L; GILBEAU, C; LACHAPELLE, J.-M et al.Annales de dermatologie et de vénéréologie. 2003, Vol 130, Num 4, pp 443-446, issn 0151-9638, 4 p.Article

GRADE 3/4 DERMATITIS IN HEAD AND NECK CANCER PATIENTS TREATED WITH CONCURRENT CETUXIMAB AND IMRTSTUDER, Gabriela; BROWN, Michelle; GLANZMANN, Christoph et al.International journal of radiation oncology, biology, physics. 2011, Vol 81, Num 1, pp 110-117, issn 0360-3016, 8 p.Article

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruptionSCOPE, Alon; LIEB, Jocelyn A; DUSZA, Stephen W et al.Journal of the American Academy of Dermatology. 2009, Vol 61, Num 4, pp 614-620, issn 0190-9622, 7 p.Article

Molecular determinants of cetuximab efficacyVALLBÖHMER, Daniel; WU ZHANG; GROSHEN, Susan et al.Journal of clinical oncology. 2005, Vol 23, Num 15, pp 3536-3544, issn 0732-183X, 9 p.Article

Cetuximab prolongs survival and improves locoregional controlJournal of cancer research and clinical oncology. 2006, Vol 132, pp 6-9, issn 0171-5216, 4 p., SUP3Conference Paper

Subcutaneous abscess as a side-effect of cetuximab therapyGUERRIERO, Cristina; RICCI, Francesco; PARADISI, Andrea et al.EJD. European journal of dermatology. 2011, Vol 21, Num 2, pp 277-278, issn 1167-1122, 2 p.Article

A desensitization protocol for the mAb cetuximab. Authors' replyJERATH, Maya R; KWAN, Mildred; KANNARKAT, Mily et al.Journal of allergy and clinical immunology. 2009, Vol 123, Num 1, pp 260-262, issn 0091-6749, 3 p.Article

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunctionKRENS, L. L; BAAS, J. M; VERBOOM, M. C et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 6, pp 1303-1306, issn 0344-5704, 4 p.Article

Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspectsGÖSTRING, Lovisa; CHEW, Ming Tsuey; ORLOVA, Anna et al.International journal of oncology. 2010, Vol 36, Num 4, pp 757-763, issn 1019-6439, 7 p.Article

Nuclear EGFR contributes to acquired resistance to cetuximabLI, C; IIDA, M; DUNN, E. F et al.Oncogene (Basingstoke). 2009, Vol 28, Num 43, pp 3801-3813, issn 0950-9232, 13 p.Article

A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatmentSHABLAK, Alaaeldin; CONN, Andrew.Targeted oncology. 2014, Vol 9, Num 2, pp 177-180, issn 1776-2596, 4 p.Article

Éruption acnéiforme au cétuximab = Cetuximab-induced aceneiform eruptionRIBOULET, J.-L.Les Nouvelles dermatologiques. 2006, Vol 25, Num 3, pp 156-157, issn 0752-5370, 2 p.Conference Paper

New approaches to enhance chemotherapy in SCCHNBOURHIS, J.Annals of oncology. 2005, Vol 16, pp vi20-vi24, issn 0923-7534, SUP6Conference Paper

An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of CetuximabCEZE, Nicolas; TERNANT, David; PILLER, Friedrich et al.Therapeutic drug monitoring. 2009, Vol 31, Num 5, pp 597-601, issn 0163-4356, 5 p.Article

The biological properties of cetuximabVINCENZI, Bruno; SCHIAVON, Gaia; SILLETTA, Marianna et al.Critical reviews in oncology/hematology. 2008, Vol 68, Num 2, pp 93-106, issn 1040-8428, 14 p.Article

Current treatments and promising investigations in a multidisciplinary settingVOKES, E.Annals of oncology. 2005, Vol 16, pp vi25-vi30, issn 0923-7534, SUP6Conference Paper

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effectiveWEHLER, Thomas C; GRAF, Claudine; MÖHLER, Markus et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 10, pp 1667-1672, issn 0171-5216, 6 p.Article

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyMARTINELLI, E; DE PALMAR, R; ORDITURA, M et al.Clinical and experimental immunology (Print). 2009, Vol 158, Num 1, pp 1-9, issn 0009-9104, 9 p.Article

Erupción acneiforme secundaria a cetuximab = Aceneiform eruption secondary to cetuximabHERRERA-ACOSTA, Enrique; MARTIN-EZQUERRA, Gemma; IGLESIAS, Maribel et al.Actas dermo-sifiliográficas (Ed. impresa). 2005, Vol 96, Num 4, pp 252-254, issn 0001-7310, 3 p.Article

Development of ¹⁷⁰Tm-DOTA-cetuximab for radioimmunotherapySHIRVANI-ARANI, Simindokht; BAHRAMI-SAMANI, Ali; JALILIAN, Amir Reza et al.Journal of labelled compounds & radiopharmaceuticals. 2012, Vol 55, Num 3-4, pp 103-107, issn 0362-4803, 5 p.Article

Interdisciplinary management of EGFR-inhibitor- induced skin reactions: a German expert opinionPOTTHOFF, K; HOFHEINZ, R; TRARBACH, T et al.Annals of oncology. 2011, Vol 22, Num 3, pp 524-535, issn 0923-7534, 12 p.Article

Mechanically-induced aggregation of the monoclonal antibody cetuximabLAHLOU, A; BLANCHET, B; CARVALHO, M et al.Annales pharmaceutiques françaises. 2009, Vol 67, Num 5, pp 340-352, issn 0003-4509, 13 p.Article